QLT Plans XR9576 NDA Filing in 2005 After In-Licensing Deal With Xenova
Executive Summary
QLT plans to seek a first-line indication for Xenova's cancer multi-drug resistance agent XR9576 in non-small cell lung cancer with a planned 2005 NDA filing.